What question did this study set out to answer?

The study evaluates the cost-effectiveness of pembrolizumab combined with chemotherapy for metastatic non-small cell lung cancer (mNSCLC).

April 10, 2026Open Access

Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison

Puntos clave

The study evaluates the cost-effectiveness of pembrolizumab combined with chemotherapy for metastatic non-small cell lung cancer (mNSCLC).
Compared cost-effectiveness of pembrolizumab plus chemotherapy using real-world evidence (RWE) and randomized controlled trial (RCT) data.
Analyzed incremental cost-effectiveness ratio (ICER) between RWE and RCT outcomes.
Focused on mNSCLC patient populations.
Found that pembrolizumab plus chemotherapy was unlikely to be cost-effective for mNSCLC.
Identified higher ICER with RWE compared to RCT data.
Suggests trial-based effectiveness may overestimate outcomes in real-world practice.

Resumen

Pembrolizumab plus platinum therapy is unlikely to be cost-effective for mNSCLC. The higher ICER with RWE compared to RCT data suggests that trial-based outcomes may overestimate effectiveness in routine practice. These findings highlight the importance of incorporating RWE into post-approval reassessment for high-cost oncology therapies.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Teppala et al. (Wed,) studied this question.

synapsesocial.com/papers/69d895be6c1944d70ce06daa https://doi.org/https://doi.org/10.1080/13696998.2026.2651038

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar

Ver artículo completo